UPB Upstream Bio Corp Total Debt to Capital

UPB (Upstream Bio Corp) - company brandmark

The implementation of automation in antibody screening has accelerated drug development, and the financial leverage dynamics of Upstream Bio Inc (UPB) now reflect a current trend where the indicator value reaches 0.00. Upstream Bio Inc (UPB) is focusing on bringing an innovative treatment for severe asthma to market, relying on contract manufacturing organizations (CMO) for the production of monoclonal antibodies.

UPB Upstream Bio All Debt to Shareholders' Equity Ratio (10/12/2024 - 10/27/2026)

Analytical breakdowns for Upstream Bio Inc

- price and consensus price forecast:
Stock Price Upstream Bio|UPB - Fair Value Consensus
- market capitalization data:
Market Capitalization Upstream Bio|UPB - Enterprise Value
- book capitalization data:
Net Assets per Single Share Upstream Bio|UPB - Accounting Value of Company|Market Value to Book Value Ratio upstreambio.com|UPB - Cumulative Company Assets
- debt and liquidity data:
Total Debt to Capital Upstream Bio Inc|UPB - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Upstream Bio Inc|UPB - Aggregate Debt Obligations|Debts to Book Capitalization Upstream Bio
Basic company analysis:Upstream Bio - UPB
Finished products of upstreambio.com

Minimizing debt risks is critical for assessing the stability of biopharmaceutical startups. The development of unique antibodies by Upstream Bio Inc (UPB) requires colossal investments in patent protection and R&D. The ratio of total liabilities to equity, reflected in the financial leverage coefficient (total debt-to-equity), determines the business's degree of dependence on external borrowing. This indicator measures the balance sheet's vulnerability to rising interest rates. A low value confirms the company's financial autonomy.

Key competitors

ARGX - Total Debt to Capital|All Debt to Shareholders' Equity Ratio BioNTech Inc.|Total Debt to Capital ABVX|Total Debt to Capital ADMA (ADMA Corp)|Debt to Equity Protagonist Therapeutics|immunovant.com - All Debt to Shareholders' Equity Ratio|KNSA: Debt to Equity|GRFS - Total Debt to Equity Ratio|ADPT: Total Debt to Capital|Total Debt to Capital Celldex Corp|AUPH - Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio biocryst.com|VERA (Vera Therapeutics) - Total Debt to Capital|Total Debt to Capital Coefficient DNTH (Dianthus Therapeutics Inc)|Pharvaris Corp - Debt to Equity|AbCellera - Total Debt to Equity Ratio|TRML: Debt to Equity|precigen.com (PGEN) - Total Debt to Equity Ratio|PHAR: Total Debt to Equity Ratio|NKTR (Nektar Therapeutics Inc) - Total Debt to Capital|Debt to Equity Zenas Biopharma, Inc. (ZBIO)|Debt to Equity Ratio Immunome Bio|Gossamer Bio, Inc. - Total Debt to Capital|Debt to Capital kalvista.com KALV|Total Debt to Equity Ratio SEPN (Septerna)|Pieris Pharma - Total Debt to Capital|Debt to Equity Savara Corp|RIGL: Aggregate Debt to Equity|AnaptysBio, Inc. - Debt to Equity|Total Debt to Capital Coefficient astriatx.com|enGene (ENGN) - Total Debt to Equity Ratio|Aggregate Debt to Capital RAPT|Aerovate Therapeutics Inc (JBIO) - Debt to Equity|All Debt to Shareholders' Equity Ratio Aclaris Therapeutics, Inc (ACRS)|KYTX: Total Debt to Capital|Debt to Capital tizianalifesciences.com TLSA|Cabaletta Bio - Total Debt to Capital|VTYX: Total Debt to Capital|THTX (Theratechnologies Inc) - Debt to Equity|Total Debt to Equity Ratio Avalo Therapeutics Inc|ELDN - Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio agenusbio.com|Total Debt to Capital Climb Bio (CLYM)|Debt to Equity Zura Bio Ltd (ZURA)|Total Debt to Capital ATYR|Adagene Inc - Total Debt to Capital Coefficient|IMA (Ikena Oncology, Inc.) - Debt to Equity|Shattuck Labs, Inc. (STTK) - Debt to Capital|Total Debt to Equity Ratio equilliumbio.com EQ|Connect Biopharma Holdings Limited (CNTB) - All Debt to Shareholders' Equity Ratio|IMUX: Total Debt to Capital|Total Debt to Capital Coefficient ATRA|Debt to Equity InflaRx N.V. IFRX|Debt to Equity Ratio x4pharma.com (XFOR)|Adicet Bio, Inc. - Total Debt to Capital|CELU - Total Debt to Equity Ratio|INmune Bio Corp - Total Debt to Equity Ratio|BRNS: Total Debt to Capital|Debt to Equity Kezar Life Sciences (KZR)|sabbiotherapeutics.com (SABS) - Aggregate Debt to Equity|Total Debt to Capital Akari Therapeutics Plc|Debt to Equity ENLV|QTTB - Debt to Equity|Aggregate Debt to Equity GeoVax Corp (GOVX)|Total Debt to Capital Edesa Biotech, Inc.|All Debt to Shareholders' Equity Ratio ibioinc.com IBIO|Carisma Tx - Total Debt to Capital|XTLB: Total Debt to Capital|Debt to Equity boltbio.com BOLT|HCWB (HCW Biologics) - All Debt to Shareholders' Equity Ratio|Debt to Equity APVO|Total Debt to Equity Ratio AIM ImmunoTech, Inc.|Total Debt to Capital ADTX|Total Debt to Capital GRI Bio Inc GRI|Total Debt to Equity Ratio XORTX|All Debt to Shareholders' Equity Ratio Vyome Therapeutics HIND|Total Debt to Capital REVB (Revelation Biosciences)|INDP: Total Debt to Capital Coefficient|SCNI (Scinai Immunotherapeutics Ltd.) - Debt to Equity|CALI (CalciMedica) - Total Debt to Equity Ratio|Debt to Equity AFMD|Total Debt to Equity Ratio Allakos Therapeutics (ALLK)|Total Debt to Equity Ratio HOOK|Total Debt to Capital IGMS (igmbio.com)|ITOS - Debt to Equity|Debt to Equity Ratio Ocean Biomedical Inc OCEA|TCBP (TC BioPharm (Holdings) PLC) - Total Debt to Capital|Third Harmonic Bio Inc (THRD) - Debt to Capital